Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

NCT06465732 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Tofacitinib

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University